arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Anika Therapeutics, Inc.

ANIK
$20.38 ▼ -0.45 (-2.18%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
18 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
27
Health
Poor
Bearish
auto_awesome

Analytical Summary

Anika Therapeutics, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $292.2M
Dividend Yield —
Revenue Growth -5.9% ↘
Op. Margin -9.8% ↘
ROIC -8.3% ↗
FCF / Share $0.30 ↗
Trailing P/E —
Price / Book 2.0x
FCF Yield 1.5%
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

18-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$112.82M
↓ -5.9% —
Net Income Profit after all expenses
$-10.88M
↑ +80.7% —
Operating Margin Operating profit as % of sales
-9.8%
↓ -130.3% 15th
FCF / Share Free cash flow per share
$0.30
↑ +292.1% —
Long-Term Debt Long-term obligations
$9.60M
↓ -14.3% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
24
Returns
36
Cash Quality
14

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 18 years · 67 quarters